Springer Nature
Browse
40425_2019_823_MOESM1_ESM.pdf (136.37 kB)

MOESM1 of Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

Download (136.37 kB)
journal contribution
posted on 2019-12-07, 04:30 authored by Julie Voeller, Amy Erbe, Jacob Slowinski, Kayla Rasmussen, Peter Carlson, Anna Hoefges, Sabrina VandenHeuvel, Ashley Stuckwisch, Xing Wang, Stephen Gillies, Ravi Patel, Alvin Farrel, Jo Rokita, John Maris, Jacquelyn Hank, Zachary Morris, Alexander Rakhmilevich, Paul Sondel
Additional file 1: Figure S1. Antitumor effect of RT, IC, anti-CTLA-4, and anti-CD40/CpG against 9464D-GD2 neuroblastoma. Tumor growth curves are shown for mice bearing intradermal 9464D-GD2 tumors (about 50mm3) that were untreated or treated with RT alone, or RT and IT-IC and anti-CTLA-4, or RT and anti-CD40/CpG, or IT-IC and anti-CTLA-4 and anti-CD40/CpG, or RT and combined IT-IC, anti-CTLA-4, and anti-CD40/CpG. Tumor-free mice on day 30 (if any) are denoted as number of CR of total mice in the group. Combined treatment with RT, IT-IC, anti-CTLA-4, and anti-CD40/CpG resulted in complete tumor regression in one mouse and in the strongest tumor growth suppression in other mice.

Funding

Hyundai Hope On Wheels

History